Longidaza Candles 3000m №10

Dosage form

Candles

Composition

1 suppository for rectal or vaginal administration contains: Longidaza with hyaluronidase activity of 3 thousand IU.

Excipients: cacao butter.

Packing

In 1 pack cell contour 5 suppositories. In a cardboard bundle 2 packaged cell contour.

Mechanism of action

Longidaza - a drug with proteolytic activity.

It has an enzymatic proteolytic (hyaluronidase) activity of prolonged action, chelating, antioxidant, immunomodulatory and moderately pronounced anti-inflammatory action.

The prolonged action is achieved by covalent binding of the enzyme with a physiologically active high molecular weight carrier (activated derivative of N-oxide poly-1.4-ethylene piperazine, an analogue of polyoxidonium), which has its own pharmacological activity.

Longidaza shows anti-fibrotic properties, weakens the acute phase of inflammation, regulates (increases or decreases, depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor-alpha), increases the humoral immune response and resistance of the organism to infection.

The expressed anti-fibrotic properties of Longidaza are provided by conjugation of hyaluronidase with a carrier, which significantly increases the resistance of the enzyme to denaturing effects and the action of inhibitors.

The enzymatic activity of Longidaza remains when heated to 37 ° C for 20 days, while native hyaluronidase under the same conditions begins to lose its activity during the day.

In the preparation of Longidaza, the simultaneous local presence of the proteolytic enzyme hyaluronidase and a carrier is provided that is capable of binding enzyme inhibitors and stimulators of collagen synthesis (iron, copper, heparin) released during hydrolysis of the matrix components. Due to these properties, Longidaza has not only the ability to depolymerize the matrix of connective tissue in fibrous granulomatous formations, but also to suppress the reverse regulatory response, aimed at the synthesis of components of connective tissue.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, Chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (breaking the bond between C 1 acetylglycosamine and C 4 glucuronic or induuro acids), glycosaminoglycans change their basic properties: viscosity decreases, the ability to bind water decreases, metal ions, the permeability of tissue barriers temporarily increases,it facilitates the movement of fluid in the intercellular space, increases the elasticity of the connective tissue, which is manifested in reducing tissue swelling, flattening scars, increasing the volume of movement of the joints, reducing contractures and preventing their formation, reducing adhesions.

Biochemical, immunological, histological and electron microscopic studies have shown that Longidaza does not damage normal connective tissue, but causes destruction of the composition and structure of the connective tissue in the area of ​​fibrosis.

Longidaza does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

The use of Longidaza in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or progression of the infectious process; does not slow down the recovery of bone tissue.

Indications and usage

Adults and adolescents over 12 years of age as monotherapy and as part of a complex therapy of diseases involving connective tissue hyperplasia (including against the background of the inflammatory process).

Longidaza is also used to increase the bioavailability of antibiotic therapy in urology, gynecology, dermatology, surgery and pulmonology.

In urology:
- Chronic prostatitis.
- Interstitial cystitis.
- Strictures of the urethra and ureters.
- Peyronie's Disease.
- The initial stage of benign prostatic hyperplasia.
- Prevention of the formation of scars and strictures after surgical interventions on the urethra, bladder, ureters.

In gynecology:
- Prevention and treatment of adhesions in the pelvis for chronic inflammatory diseases of the internal genital organs.
- Prevention and treatment of adhesions in the pelvis after gynecological procedures (including artificial abortions, previous surgical interventions on the pelvic organs).
- Intrauterine synechia.
- Tube-peritoneal infertility.
- Chronic endomyometritis.

In dermatology and venereology:
- Limited scleroderma.
- Prevention of fibrous complications of sexually transmitted infections.

In surgery:
- Prevention and treatment of adhesions after surgery on the abdominal organs.
- Long-lasting wounds.

In pulmonology and phthisiology:
- Pneumofibrosis.
- Sideros.
- Tuberculosis (cavernous-fibrous, infiltrative, tuberculoma).
- Interstitial pneumonia.
- Fibrosing alveolitis.
- Pleurisy.

Contraindications

- Malignant neoplasms.
- Pregnancy (no clinical experience).
- Children's age up to 12 years (efficacy and safety of the drug has not been studied).
- Hypersensitivity to the drug.
- Increased individual sensitivity to drugs with hyaluronidase activity.

With caution and no more than 1 time per week to use in patients with renal insufficiency, pulmonary hemorrhage in history.

Pregnancy and Breastfeeding

The drug is contraindicated for use in pregnancy.

Data on the safety of the drug during lactation is not provided.

Longidaza has no embryotoxic and teratogenic effects.

Dosage and administration

Longidaza in the form of suppositories is recommended for rectal or intravaginal use 1 time per day for the night, for the course - 10-20 injections.

Rectal: 1 suppository 1 time / day after bowel cleansing.

Intravaginal: 1 suppository 1 time / day for the night; The suppository is inserted into the vagina while lying down.

The treatment regimen is adjusted depending on the severity, stage and duration of the disease. Perhaps the appointment of the drug every other day or with intervals of 2-3 days.

If necessary, a repeated course of Longidaza is recommended no earlier than in three months or long-term supportive therapy - 1 suppository 1 time / 5-7 days for 3-4 months.

Recommended treatment regimens:

In urology - 1 suppository every other day - 10 injections, then in 2-3 days - 10 injections. General course of 20 introductions.

In gynecology - rectally or intravaginally, 1 suppository in 2 days - 10 injections, then, if necessary, supportive therapy is prescribed.

In dermatology and venereology - 1 suppository in 1–2 days - 10–15 injections.

In surgery - 1 suppository after 2-3 days - 10 injections.

In pulmonology and phthisiology - 1 suppository in 2-4 days - 10–20 knowledge.

Adverse reactions

Seldom: allergic reactions at the increased individual sensitivity.

Special notes

When applied against the background of exacerbation of foci of infection to prevent the spread of infection, prescribe under the cover of antimicrobial agents.

With the development of an allergic reaction should immediately discontinue the use of Longidaza.

Longidaza does not have a mutagenic and carcinogenic effect.

With caution and no more than 1 time per week to apply in patients with renal insufficiency.

With the use of Longidaza in patients receiving salicylates, Cortisone, ACTH, estrogen, or high-dose antihistamines, the effectiveness of the enzyme hyaluronidase can be reduced.

When prescribed in combination with other drugs, consideration should be given to the possibility of increasing their absorption (bioavailability) and enhancing systemic action.

Store in a dry, dark place at a temperature from + 8 ° С to + 15 ° С.

2 years.